Research activity information

• The role of LAT1 in AOM/DSS-induced colorectal tumorigenesis

  Yunlong Sui, Namiko Hoshi, Norihiro Okamoto, Yuta Inoue, Takumi Funatsu, Yuna Ku, Makoto Ooi, Daisuke Watanabe, Haruka Miyazaki, Misaki Agawa, Hirotaka Nakamura, Ryuichi Ohgaki, Yoshikatsu Kanai, Hui Yang, Yuzo Kodama

  Elsevier BV, Feb. 2025, Biochemical and Biophysical Research Communications, 151446 - 151446

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis.

  Haruka Miyazaki, Namiko Hoshi, Tsukasa Ishida, Chiharu Nishioka, Sachiko Ouchi, Daisuke Shirasaka, Tomoo Yoshie, Yoshinori Munetomo, Yoshio Sakamoto, Tatsuya Osuga, Saori Matsui, Toshiki Hyodo, Tamami Denda, Daisuke Watanabe, Makoto Ooi, Yuzo Kodama

  Not all patients with ulcerative colitis (UC) respond initially to treatment with biologic agents, and predicting their efficacy prior to treatment is difficult. Vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 (α4β7) integrin, suppresses immune cell migration by blocking the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule 1. Reports about histological features that predict vedolizumab efficacy are scarce. So, we examined the association between histological features and vedolizumab efficacy. This was a multicenter, retrospective study of patients with UC treated with vedolizumab. Biopsy specimens taken from the colonic mucosa prior to vedolizumab induction were used, and the areas positively stained for CD4, CD68, and CD45 were calculated. Clinical and histological features were compared between those with and without remission at week 22, and the factors associated with clinical outcomes were identified. We enrolled 42 patients. Patients with a high CD4+ infiltration showed a better response to vedolizumab [odds ratio (OR) = 1.44, P = 0.014]. The concomitant use of corticosteroids and high Mayo scores had a negative association with the vedolizumab response (OR = 0.11, P = 0.008 and OR = 0.50, P = 0.009, respectively). Histological evaluation for CD4+ cell infiltration may be helpful in selecting patients who can benefit from vedolizumab.

  Nov. 2023, Scientific reports, 13(1) (1), 20262 - 20262, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan.

  Haruka Miyazaki, Daisuke Watanabe, Yuki Ito, Sayaka Ikeda, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Makoto Ooi, Namiko Hoshi, Yuzo Kodama

  BACKGROUND/PURPOSE OF THIS STUDY: It has been recommended that individuals with inflammatory bowel disease (IBD) be vaccinated against Coronavirus disease - 19 (COVID-19). Recently, we documented the incidence of side effects (SEs) after COVID-19 immunization among individuals with IBD in Japan. However, the study did not show differences between the types of IBD or the patients' clinical backgrounds. In this survey, we aimed at investigating whether the frequency of SEs differed among patients with IBD. METHODS: A cross-sectional survey was conducted among adult patients with IBD at Kobe University between March 2022 and September 2022. RESULTS: Total 195 patients, including 134 with ulcerative colitis (UC) and 61 with Crohn's disease (CD), completed the questionnaire and were included in the analysis. Of these, 92.3%, 91.3% and 44.1% received the initial, second and third dose of the COVID-19 vaccine, respectively. The frequency of local symptoms following the initial, second and third dose of the vaccine was comparable between patients with UC and CD (69.6% vs. 72.7%, 64.2% vs. 69.1% and 63.5% vs. 73.9%, respectively). Muscle pain after the initial and second doses of the COVID-19 vaccine was more common among patients treated with corticosteroids (58.1% vs. 37.6% and 60.0% vs. 31.8%, p < 0.05). Female sex, younger age and current or former smoking were associated with an increased incidence of fever or chills after the initial dose of the vaccine (p < 0.05). In contrast, corticosteroid use was identified as a factor associated with an increased incidence of muscle pain after the initial dose of vaccine (p < 0.05). CONCLUSION: The use of corticosteroids could increase the risk of muscle pain following COVID-19 vaccination. Additionally, factors such as female sex, younger age and current or former smoking can affect the incidence of fever or chills. This information should encourage patients with IBD to get vaccinated against COVID-19.

  Oct. 2023, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 42(5) (5), 701 - 707, English, International magazine

  Scientific journal


• Disseminated Mycobacterium avium Complex Infection in a Patient Treated With Immunosuppressants.

  Yuki Ito, Daisuke Watanabe, Sayaka Ikeda, Norihiro Okamoto, Haruka Miyazaki, Eri Tokunaga, Yuna Ku, Makoto Ooi, Namiko Hoshi, Yuzo Kodama

  Mycobacterium avium complex (MAC) is an important cause of opportunistic infections in immunosuppressed hosts, such as patients with HIV infection and solid organ transplant recipients. MAC disease usually presents in 4 distinct clinical categories: chronic pulmonary disease, disseminated disease, skin/soft-tissue infection, and superficial lymphadenitis. However, clinical reports on gastrointestinal (GI) MAC disease are rare, especially in patients without HIV infection or a history of organ transplantation. We describe a case of non-HIV-associated GI MAC disease in a patient with long-term mycophenolate mofetil use. In this case, MAC organisms in the GI tract and ascites were observed. Endoscopy revealed a unique colonic image with large, deep epithelial denudations. This suggests that apart from patients with HIV infection or transplant recipients, those treated with immunosuppressants can have disseminated MAC. Therefore, internal physicians need to monitor patients undergoing mycophenolate mofetil immunosuppressant therapy.

  Apr. 2023, ACG case reports journal, 10(4) (4), e01033, English, International magazine


• 一過性の細胞免疫不全所見を認めた超早期発症型炎症性腸疾患の1例

  福田 拓弥, 堀之内 智子, 近藤 淳, 宮崎 はる香, 田村 彰広, 大片 祐一, 増田 知佳, 北角 英晶, 具 潤亜, 渡邉 大輔, 星 奈美子, 榊原 菜々, 山本 暢之, 大井 充, 尾藤 祐子, 森 一越, 野津 寛大

  (公社)日本小児科学会, Apr. 2023, 日本小児科学会雑誌, 127(4) (4), 625 - 626, Japanese


• 当院における小児炎症性腸疾患症例の総括と検討

  近藤 淳, 堀之内 智子, 岡本 典大, 吉村 翔平, 市川 裕太, 田中 悠, 上田 知佳, 北角 英晶, 榊原 菜々, 渡邊 大輔, 星 奈美子, 大片 祐一, 大井 充, 尾藤 祐子, 児玉 裕三, 野津 寛大

  (一社)日本小児栄養消化器肝臓学会, Apr. 2023, 日本小児栄養消化器肝臓学会雑誌, 37(1) (1), 35 - 35, Japanese


• LAT1 expression influences Paneth cell number and tumor development in ApcMin/+ mice

  Yunlong Sui, Namiko Hoshi, Ryuichi Ohgaki, Lingling Kong, Ryutaro Yoshida, Norihiro Okamoto, Masato Kinoshita, Haruka Miyazaki, Yuna Ku, Eri Tokunaga, Yuki Ito, Daisuke Watanabe, Makoto Ooi, Masakazu Shinohara, Kengo Sasaki, Yoh Zen, Takenori Kotani, Takashi Matozaki, Zibin Tian, Yoshikatsu Kanai, Yuzo Kodama

  Abstract Background Amino acid transporters play an important role in supplying nutrition to cells and are associated with cell proliferation. L-type amino acid transporter 1 (LAT1) is highly expressed in many types of cancers and promotes tumor growth; however, how LAT1 affects tumor development is not fully understood. Methods To investigate the role of LAT1 in intestinal tumorigenesis, mice carrying LAT1 floxed alleles that also expressed Cre recombinase from the promoter of gene encoding Villin were crossed to an Apc^Min/+ background (LAT1^fl/fl; vil-cre; Apc^Min/+), which were subject to analysis; organoids derived from those mice were also analyzed. Results This study showed that LAT1 was constitutively expressed in normal crypt base cells, and its conditional deletion in the intestinal epithelium resulted in fewer Paneth cells. LAT1 deletion reduced tumor size and number in the small intestine of Apc^Min/+ mice. Organoids derived from LAT1-deleted Apc^Min/+ intestinal crypts displayed fewer spherical organoids with reduced Wnt/β-catenin target gene expression, suggesting a low tumor-initiation capacity. Wnt3 expression was decreased in the absence of LAT1 in the intestinal epithelium, suggesting that loss of Paneth cells due to LAT1 deficiency reduced the risk of tumor initiation by decreasing Wnt3 production. Conclusions LAT1 affects intestinal tumor development in a cell-extrinsic manner through reduced Wnt3 expression in Paneth cells. Our findings may partly explain how nutrient availability can affect the risk of tumor development in the intestines.

  Springer Science and Business Media LLC, Feb. 2023, Journal of Gastroenterology, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan.

  Haruka Miyazaki, Daisuke Watanabe, Yuki Ito, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Makoto Ooi, Namiko Hoshi, Yuzo Kodama

  BACKGROUND: Patients with inflammatory bowel disease (IBD) are recommended to receive the coronavirus disease 2019 (COVID-19) vaccine. However, a recent survey showed that patients with IBD are more hesitant to receive the vaccine than the general population. Detailed information on the side effects of the COVID-19 vaccine is necessary to encourage vaccination among patients with IBD. AIM: To investigate the frequency of side effects following COVID-19 vaccination in patients with IBD in Japan. STUDY DESIGN: a cross-sectional survey was conducted using a questionnaire administered to adult patients with IBD in a tertiary medical facility. RESULTS: Among the participants who answered the questionnaire, 92.6%, 91.5%, and 41.5% of the participants had received their first, second, and third doses of the COVID-19 vaccine, respectively. Of the vaccinated participants, 88.3%, 86.3%, and 89.0% experienced side effects after receiving the first, second, and third doses of the vaccine, respectively. The incidences of fever, chills, and headaches were significantly higher among female participants than among male participants (p < 0.05). However, the frequencies of most side effects were comparable between the BNT162b2 mRNA and mRNA-1273 vaccines. CONCLUSION: The findings of our survey can help encourage patients with IBD to receive the COVID-19 vaccine.

  Sep. 2022, Digestive diseases and sciences, English, International magazine

  Scientific journal


• Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.

  Haruka Miyazaki, Daisuke Watanabe, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Haruka Takenaka, Namiko Hoshi, Makoto Ooi, Yuzo Kodama

  BACKGROUND: Behçet's disease (BD) is a recurrent multisystem inflammatory disease. Anti-tumor necrosis factor (TNF) α agents have been used to treat patients with intestinal BD with severe disease activity or those who are resistant to conventional treatments; however, the long-term efficacy of anti-TNFα agents in intestinal BD remains unclear. In the present study, we investigated the clinical outcomes and predictors of discontinuation of anti-TNFα agents in patients with intestinal BD. METHODS: We reviewed the medical records of patients with intestinal BD who received first-line anti-TNFα agents between January 2009 and June 2020. The primary outcome was the percentage of patients who continued anti-TNFα therapy for 48 weeks. Secondary outcomes included the percentage of patients who achieved marked improvement, complete remission, and mucosal healing, as well as predictors of discontinuation of anti-TNFα agents. RESULTS: A total of 29 patients were included in the study. Twenty-two (75.9%) patients continued anti-TNFα therapy for 48 weeks. The percentage of patients who achieved marked improvement, complete remission, and mucosal healing at week 48 was 48.3%, 37.9%, and 48.3%, respectively. At week 96, 11 (37.9%) patients achieved marked improvement, complete remission, and mucosal healing. A higher C-reactive protein level (CRP; ≥ 1 mg/dL) at baseline was a predictor of discontinuation of anti-TNFα agents. CONCLUSIONS: The 48-week continuation rate of anti-TNFα agents was 75.9% in bio-naïve patients with intestinal BD. However, a higher baseline CRP level (≥ 1 mg/dL) was associated with discontinuation of anti-TNFα agents.

  Mar. 2022, BMC gastroenterology, 22(1) (1), 149 - 149, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 当院における潰瘍性大腸炎での5-ASA不耐症の現状について

  岡本 典大, 宮崎 はる香, 徳永 英里, 松本 慶, 具 潤亜, 竹中 春香, 大井 充, 星 奈美子, 児玉 裕三

  (一財)日本消化器病学会, Mar. 2021, 日本消化器病学会雑誌, 118(臨増総会) (臨増総会), A350 - A350, Japanese


• 吸収不良症候群診療の進歩と課題 Lipomatous pseudohypertrophy of the pancreasの2例

  宮崎 はる香, 大井 充, 星 奈美子, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 114回, 40 - 40, Japanese


• 小腸多発血管異形成に対するダブルバルーン内視鏡、およびアルゴンプラズマ凝固術後に、遅発性小腸穿孔を来たした一例

  吉治 誠, 松本 慶, 鷹尾 俊達, 岡本 典大, 宮崎 はる香, 松岡 晃生, 竹中 春香, 大井 充, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2021, 日本消化器病学会近畿支部例会プログラム・抄録集, 114回, 72 - 72, Japanese


• A case of autoimmune enteropathy with CTLA4 haploinsufficiency.

  Haruka Miyazaki, Namiko Hoshi, Michitaka Kohashi, Eri Tokunaga, Yuna Ku, Haruka Takenaka, Makoto Ooi, Nobuyuki Yamamoto, Suguru Uemura, Noriyuki Nishimura, Kazumoto Iijima, Keisuke Jimbo, Tsubasa Okano, Akihiro Hoshino, Kohsuke Imai, Hirokazu Kanegane, Ichiro Kobayashi, Yuzo Kodama

  Autoimmune enteropathy (AIE) is a rare disease, characterized by intractable diarrhea, villous atrophy of the small intestine, and the presence of circulating anti-enterocyte autoantibodies. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, and mutations in FOXP3, which is a master gene of regulatory T cells (Tregs), are major causes of AIE. Recent studies have demonstrated that mutations in other Treg-associated genes, such as CD25 and CTLA4, show an IPEX-like phenotype. We present the case of a 13-year-old girl with CTLA4 haploinsufficiency, suffering from recurrent immune thrombocytopenic purpura and intractable diarrhea. We detected an autoantibody to the AIE-related 75 kDa antigen (AIE-75), a hallmark of the IPEX syndrome, in her serum. She responded well to a medium dose of prednisolone and a controlled dose of 6-mercaptopurine (6-MP), even after the cessation of prednisolone administration. Serum levels of the soluble interleukin-2 receptor and immunoglobulin G (IgG) were useful in monitoring disease activity during 6-MP therapy. In conclusion, autoimmune-mediated mechanisms, similar to the IPEX syndrome, may be involved in the development of enteropathy in CTLA4 haploinsufficiency. Treatment with 6-MP and monitoring of disease activity using serum levels of soluble interleukin-2 receptor and IgG is suggested for such cases.

  Jan. 2021, Intestinal research, English, International magazine

  Link to Kobe Univ. Repository (Kernel)


• Effect of Daikenchuto On Spontaneous Intestinal Tumors in ApcMin/+ Mice.

  Lingling Kong, Namiko Hoshi, Daisuke Watanabe, Yasutaka Yamada, Eiichiro Yasutomi, Soichiro Adachi, Makoto Ooi, Yunlong Sui, Ryutaro Yoshida, Ryohei Sekimoto, Eri Tokunaga, Haruka Miyazaki, Yuna Ku, Haruka Takenaka, Tadao Kunihiro, Jun Inoue, Zibin Tian, Yuzo Kodama

  Daikenchuto (TU-100) is herbal medicine which predominantly contains ginger, Japanese pepper, and ginseng. We investigated whether TU-100 can affect the composition of gut flora and intestinal tumor development using ApcMin/+ mice, a murine model of intestinal tumor. Bacterial 16S rRNA sequencing and short-chain fatty acid analysis were performed on faecal samples. Tumor number and size were analysed. Any change in gene expression of the tumor tissues was assessed by real-time PCR. Principal coordinate analysis (PCoA) showed that the faecal microbiota cluster of TU-100-fed mice was different from the microbiota of control mice. However, no significant difference was observed in the concentration of short-chain fatty acids, tumor number, and gene expression levels between the two groups. Our data showed that TU-100 can affect the intestinal environment; however, it does not contribute in tumor progression or inhibition in our setting.

  Jan. 2021, The Kobe journal of medical sciences, 66(4) (4), E139-E148, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• GPR43 suppresses intestinal tumor growth by modification of the mammalian target of rapamycin complex 1 activity in ApcMin/+ mice

  Lingling Kong, Namiko Hoshi, Yunlong Sui, Yasutaka Yamada, Ryutaro Yoshida, Makoto Ooi, Zibin Tian, Ikuo Kimura, Yuzo Kodama

  S. Karger AG, 2021, Medical Principles and Practice, English

  Scientific journal


• NSAIDs外用薬によって多発小腸潰瘍をきたした1例

  城端 慧, 津田 一範, 田中 心和, 乾 沙苗, 宮崎 はる香, 徳永 英里, 賀来 英俊, 阿部 洋文, 具 潤亜, 迫 智也, 池澤 伸明, 若原 ちか, 大井 充, 鷹尾 まど佳, 鷹尾 俊達, 飛松 和俊, 森田 圭紀, 豊永 高史, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2020, 日本消化器病学会近畿支部例会プログラム・抄録集, 112回, 110 - 110, Japanese


• ベーチェット病に伴う仙腸関節炎に対して抗TNFα阻害薬で治療中に、食道穿通病変と回盲部潰瘍が出現し、内科的治療で治療しえた腸管型ベーチェット病の1例

  能瀬 洋子, 井上 綾華, 上田 洋, 宮崎 はる香, 大井 充, 岡野 隆一, 千藤 荘, 明石 健吾, 大西 輝, 星 奈美子, 三枝 淳, 児玉 裕三, 森信 暁雄

  日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 112 - 112, Japanese

  [Refereed]


• ステロイドへの反応性が良好であった小腸リンパ管拡張症の1例

  中井 沙紀, 具 潤亜, 上田 千勢, 松本 慶, 竹中 春香, 大井 充, 星 奈美子, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 82 - 82, Japanese

  [Refereed]


• NUDT15遺伝子R139C多型を背景とし、アザチオプリンによる無顆粒球症を発症した潰瘍性大腸炎の1例

  塚本 祥太, 渡邉 大輔, 大塚 崇史, 大井 充, 阪口 博哉, 具 潤亜, 山入 春香, 阿部 洋文, 迫 智也, 星 奈美子, 吉田 優, 児玉 祐三

  日本消化器病学会-近畿支部, Feb. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110回, 85 - 85, Japanese

  [Refereed]


• A comparison of the resection rate for cold and hot snare polypectomy for 4-9 mm colorectal polyps: a multicentre randomised controlled trial (CRESCENT study).

  Takuji Kawamura, Yoji Takeuchi, Satoshi Asai, Isao Yokota, Eisuke Akamine, Minoru Kato, Takuji Akamatsu, Kazuhiro Tada, Yoriaki Komeda, Mineo Iwatate, Ken Kawakami, Michiko Nishikawa, Daisuke Watanabe, Atsushi Yamauchi, Norimasa Fukata, Masaaki Shimatani, Makoto Ooi, Koichi Fujita, Yasushi Sano, Hiroshi Kashida, Satoru Hirose, Hiroyoshi Iwagami, Noriya Uedo, Satoshi Teramukai, Kiyohito Tanaka

  OBJECTIVE: To investigate the success rate of cold snare polypectomy (CSP) for complete resection of 4-9 mm colorectal adenomatous polyps compared with that of hot snare polypectomy (HSP). DESIGN: A prospective, multicentre, randomised controlled, parallel, non-inferiority trial conducted in 12 Japanese endoscopy units. Endoscopically diagnosed sessile adenomatous polyps, 4-9 mm in size, were randomly assigned to the CSP or HSP group. After complete removal of the polyp using the allocated technique, biopsy specimens from the resection margin after polypectomy were obtained. The primary endpoint was the complete resection rate, defined as no evidence of adenomatous tissue in the biopsied specimens, among all pathologically confirmed adenomatous polyps. RESULTS: A total of 796 eligible polyps were detected in 538 of 912 patients screened for eligibility between September 2015 and August 2016. The complete resection rate for CSP was 98.2% compared with 97.4% for HSP. The non-inferiority of CSP for complete resection compared with HSP was confirmed by the +0.8% (90% CI -1.0 to 2.7) complete resection rate (non-inferiority p<0.0001). Postoperative bleeding requiring endoscopic haemostasis occurred only in the HSP group (0.5%, 2 of 402 polyps). CONCLUSIONS: The complete resection rate for CSP is not inferior to that for HSP. CSP can be one of the standard techniques for 4-9 mm colorectal polyps. (Study registration: UMIN000018328).

  Nov. 2018, Gut, 67(11) (11), 1950 - 1957, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria.

  Eiichiro Yasutomi, Namiko Hoshi, Soichiro Adachi, Takafumi Otsuka, Lingling Kong, Yuna Ku, Haruka Yamairi, Jun Inoue, Tsukasa Ishida, Daisuke Watanabe, Makoto Ooi, Masaru Yoshida, Tomoya Tsukimi, Shinji Fukuda, Takeshi Azuma

  BACKGROUND AND AIMS: Proton pump inhibitors (PPIs) are among the most frequently prescribed medications. Side effects including an increased risk of intestinal infections have been reported. It is assumed that PPIs can increase susceptibility to enteropathogens; however, the underlying mechanisms are unknown. Here in this study, we explored whether Lansoprazole (Laz), one of the PPIs, increases the susceptibility to enteropathogens, and further investigated the mechanism of it. METHODS: Mice were administered Laz intraperitoneally once daily and orally infected with Citrobacter rodentium (C. rodentium). The establishment of intestinal infection was assessed by histology and inflammatory cytokine expression levels measured by quantitative PCR. To test whether Laz changes the intestinal environment to influence the susceptibility, intestinal pH, microbiota, metabolites and immune cell distributions were evaluated via pH measurement, 16S rRNA gene sequencing, metabolome, and flow cytometry analyses after Laz administration. RESULTS: Colitis was induced with less C. rodentium in Laz-treated mice as compared with the controls. We found that increased numbers of C. rodentium could reach the cecum following Laz administration. Laz increased pH in the stomach but not in the intestines. It induced dysbiosis and changed the metabolite content of the small intestine. However, these changes did not lead to alterations of immune cell distribution. CONCLUSIONS: Laz raised susceptibility to C. rodentium as increased numbers of the pathogen reach the site of infection. Our results suggest that it was due to increased stomach pH which allowed more peroral enteropathogens to pass the stomach, but not because of changes of intestinal environment.

  Apr. 2018, Digestive diseases and sciences, 63(4) (4), 881 - 889, English, International magazine

  [Refereed]

  Scientific journal


• Clinical outcomes of deep invasive submucosal colorectal cancer after ESD.

  Daisuke Watanabe, Takashi Toyonaga, Makoto Ooi, Tetsuya Yoshizaki, Yoshiko Ohara, Shinwa Tanaka, Fumiaki Kawara, Tsukasa Ishida, Yoshinori Morita, Eiji Umegaki, Takeru Matsuda, Yasuo Sumi, Mari Nishio, Hiroshi Yokozaki, Takeshi Azuma

  BACKGROUND AND STUDY AIMS: Endoscopic submucosal dissection (ESD) is a reliable method that can replace surgery under certain conditions. However, limited information is available on the clinical course of T1b colorectal cancer (CRC) after ESD. The aim of the study was to clarify the feasibility of ESD for T1b CRC. PATIENTS AND METHODS: Three hundred and two patients with 312 T1 CRC were identified in this retrospective cohort study. All patients were treated with ESD, other endoscopic treatments, or surgery. In this study, we (I) investigated the en bloc resection rate of ESD and (II) compared the overall survival (OS) rate for patients who underwent ESD with additional surgery (Group A) and surgery without upfront endoscopic resection (Group B) for T1b CRC. RESULTS: No significant differences were observed in the en bloc resection rates between T1b and T1a CRC (100 vs. 98.7%), but the en bloc R0 resection rate was significantly lower in T1b CRC than in T1a CRC (64.7 vs. 97.4%). Regarding complications, perforations occurred in 2.9% of patients with T1b CRC, which was not significantly different from the rate of 5.3% in patients with T1a CRC. No significant differences were observed in the OS or recurrence-free survival (RFS) curves between Groups A and B (OS rates at 5 years: 92.3 vs. 88.9%, RFS rates at 5 years: 81.4 vs. 85.3%). Similarly, the 5-year disease-specific survival (DSS) rate of Group A was identical to that of Group B (both 100%). CONCLUSIONS: ESD for T1b CRC before surgery is a possible strategy because of the low rate of complications and favorable long-term outcomes.

  Apr. 2018, Surgical endoscopy, 32(4) (4), 2123 - 2130, English, International magazine

  [Refereed]

  Scientific journal


• Short-term and long-term outcomes of infliximab and tacrolimus treatment for moderate to severe ulcerative colitis: Retrospective observational study

  Takafumi Otsuka, Makoto Ooi, Kazutoshi Tobimatsu, Chika Wakahara, Daisuke Watanabe, Soichiro Adachi, Eiichiro Yasutomi, Haruka Yamairi, Yuna Ku, Masaru Yoshida, Namiko Hoshi, Yuzo Kodama

  2018, Kobe Journal of Medical Sciences, 64(4) (4), E140 - E148, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.

  Fumiaki Kawara, Tsuyoshi Fujita, Yoshinori Morita, Atsushi Uda, Atsuhiro Masuda, Masaya Saito, Makoto Ooi, Tsukasa Ishida, Yasuyuki Kondo, Shiei Yoshida, Tatsuya Okuno, Yoshihiko Yano, Masaru Yoshida, Hiromu Kutsumi, Takanobu Hayakumo, Kazuhiko Yamashita, Takeshi Hirano, Midori Hirai, Takeshi Azuma

  AIM: To elucidate the factors associated with residual gastroesophageal reflux disease (GERD) symptoms in patients receiving proton pump inhibitor (PPI) maintenance therapy in clinical practice. METHODS: The study included 39 GERD patients receiving maintenance PPI therapy. Residual symptoms were assessed using the Frequency Scale for Symptoms of GERD (FSSG) questionnaire and the Gastrointestinal Symptom Rating Scale (GSRS). The relationships between the FSSG score and patient background factors, including the CYP2C19 genotype, were analyzed. RESULTS: The FSSG scores ranged from 1 to 28 points (median score: 7.5 points), and 19 patients (48.7%) had a score of 8 points or more. The patients' GSRS scores were significantly correlated with their FSSG scores (correlation coefficient = 0.47, P < 0.005). In erosive esophagitis patients, the FSSG scores of the CYP2C19 rapid metabolizers (RMs) were significantly higher than the scores of the poor metabolizers and intermediate metabolizers (total scores: 16.7 ± 8.6 vs 7.8 ± 5.4, P < 0.05; acid reflux-related symptom scores: 12 ± 1.9 vs 2.5 ± 0.8, P < 0.005). In contrast, the FSSG scores of the CYP2C19 RMs in the non-erosive reflux disease patients were significantly lower than those of the other patients (total scores: 5.5 ± 1.0 vs 11.8 ± 6.3, P < 0.05; dysmotility symptom-related scores: 1.0 ± 0.4 vs 6.0 ± 0.8, P < 0.01). CONCLUSION: Approximately half of the GERD patients receiving maintenance PPI therapy had residual symptoms associated with a lower quality of life, and the CYP2C19 genotype appeared to be associated with these residual symptoms.

  Mar. 2017, World journal of gastroenterology, 23(11) (11), 2060 - 2067, English, International magazine

  [Refereed]


• Indigo Naturalis Ameliorates Oxazolone-Induced Dermatitis but Aggravates Colitis by Changing the Composition of Gut Microflora

  Soichiro Adachi, Namiko Hoshi, Jun Inoue, Eiichiro Yasutomi, Takafumi Otsuka, Ramesh Dhakhwa, Zi Wang, Yuna Koo, Toshihiro Takamatsu, Yuriko Matsumura, Haruka Yamairi, Daisuke Watanabe, Makoto Ooi, Toshihito Tanahashi, Shin Nishiumi, Masaru Yoshida, Takeshi Azuma

  2017, INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 173(1) (1), 23 - 33, English

  [Refereed]

  Scientific journal


• 診断に苦慮した好酸球性胃腸炎の1例

  西川倫子, Ooi Makoto, 寺島禎彦, 小畑大輔, 吉江智朗, 竹中完, Shiomi Hideyuki, 藤田剛, 東健, 森永友紀子

  (一社)日本消化器内視鏡学会, Jul. 2016, Gastroenterological Endoscopy, 58(7) (7), 1215 - 1220, Japanese

  [Refereed]

  Scientific journal


• A case of eosinophilic gastroenteritis with difficulty in its diagnosis

  Michiko Nishikawa, Makoto Ooi, Yoshihiko Terashima, Daisuke Obata, Tomoo Yoshie, Mamoru Takenaka, Hideyuki Shiomi, Tsuyoshi Fujita, Takeshi Azuma, Yukiko Morinaga

  Jan. 2016, Gastroenterological Endoscopy, 58, 1215 - 1220


• A novel gas chromatography mass spectrometry-based serum diagnostic and assessment approach to ulcerative colitis

  Kohashi M, Nishiumi Sin, Ooi M, Yoshie T, Matsubara A, Suzuki M, Hoshi Namiko, Kamikozuru K, Yokoyama Y, Fukunaga K, Nakamura S, Azuma Takeshi, Yoshida Masaru

  Sep. 2014, J Crohns Colitis, 8(9) (9), 1010 - 21, English

  [Refereed]

  Scientific journal


• Successful treatment of Cronkhite-Canada syndrome using anti-tumor necrosis factor antibody therapy.

  Daisuke Watanabe, Makoto Ooi, Namiko Hoshi, Michitaka Kohashi, Tomoo Yoshie, Nobunao Ikehara, Masaru Yoshida, Emmy Yanagita, Takashi Yamasaki, Tomoo Itoh, Takeshi Azuma

  2014, Endoscopy, 46 Suppl 1 UCTN(Suppl 1 UCTN) (Suppl 1 UCTN), E476-7 - 7, English, International magazine

  [Refereed]

  Scientific journal


• APC遺伝子変異が大腸癌の代謝プロファイルに与える影響についての検討

  吉江 智郎, Nishiumi Sin, 孝橋 道敬, 小林 隆, 池田 篤紀, 坂井 文, 大井 充, Shiomi Yuki, 吉田 優, 東 健

  Feb. 2013, 日本消化器病学会雑誌, 110(臨増総会) (臨増総会), A211, Japanese

  Research society


• PPIによる維持療法を行っているGERD患者の臨床的特徴

  Fujita Tsuyoshi, Ishida Tsukasa, Morita Yoshinori, Yano Yoshihiko, Okuno Tatsuya, Ooi Makoto, Kutsumi Hiromu, Hayakumo Takanobu, Azuma Takeshi

  (一財)日本消化器病学会, Sep. 2012, 日本消化器病学会雑誌, 109(臨増大会) (臨増大会), A769 - A769, Japanese

  [Refereed]

  Research society


• GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium

  Shiomi Yuki, Nishiumi Sin, Ooi M, Hatano Naoya, Shinohara Masakazu, Yoshie T, Kondo Y, Furumatsu K, Shiomi Hideyuki, Kutsumi Hiromu, Azuma Takeshi, Yoshida Masaru

  Nov. 2011, Inflamm Bowel Dis, 17(11) (11), 2261 - 74, English

  [Refereed]

  Scientific journal


• A role of the aryl hydrocarbon receptor in attenuation of colitis

  Furumatsu K, Nishiumi Sin, Kawano Y, Ooi M, Yoshie T, Shiomi Yuki, Kutsumi Hiromu, Ashida H, Fujii-Kuriyama Y, Azuma Takeshi, Yoshida Masaru

  Sep. 2011, Dig Dis Sci, 56(9) (9), 2532 - 44, English

  [Refereed]

  Scientific journal


• GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis

  Makoto Ooi, Shin Nishiumi, Tomoo Yoshie, Yuuki Shiomi, Michitaka Kohashi, Ken Fukunaga, Shiro Nakamura, Takayuki Matsumoto, Naoya Hatano, Masakazu Shinohara, Yasuhiro Irino, Tadaomi Takenawa, Takeshi Azuma, Masaru Yoshida

  Sep. 2011, INFLAMMATION RESEARCH, 60(9) (9), 831 - 840, English

  [Refereed]

  Scientific journal


• 当院における食道表在癌の内視鏡的治療について

  Morita Yoshinori, Toyonaga Takashi, Azuma Takeshi

  (一社)日本消化器内視鏡学会, Sep. 2008, Gastroenterological Endoscopy, 50(Suppl.2) (Suppl.2), 2254 - 2254, Japanese

  International conference proceedings


• 当院で経験した中・下咽頭微小癌の検討

  Morita Yoshinori, Toyonaga Takashi, Azuma Takeshi

  (一社)日本消化器内視鏡学会, Apr. 2008, Gastroenterological Endoscopy, 50(Suppl.1) (Suppl.1), 919 - 919, Japanese

  International conference proceedings

• 潰瘍性大腸炎の発症時に免疫性血小板減少症を合併した1例

  今川 幸人, 堀之内 智子, 近藤 淳, 岡本 典大, 宮崎 はる香, 田中 悠, 市川 裕太, 上田 知佳, 北角 英晶, 田村 彰広, 渡邉 大輔, 山本 暢之, 榊原 菜々, 大井 充, 星 奈美子, 児玉 祐三, 野津 寛大

  (公社)日本小児科学会, Apr. 2024, 日本小児科学会雑誌, 128(4) (4), 624 - 624, Japanese


• 当院における潰瘍性大腸炎での5-ASA不耐症の現状について

  岡本典大, 宮崎はる香, 徳永英里, 松本慶, 具潤亜, 竹中春香, 大井充, 星奈美子, 児玉裕三

  2021, 日本消化器病学会雑誌(Web), 118


• CCSに合併した胃癌の1例

  徳永英里, 宮崎はる香, 松本慶, 阪口博哉, 具潤亜, 竹中春香, 大井充, 星奈美子, 児玉裕三, 掛地吉弘

  (一社)日本消化管学会, 2020, 日本消化管学会雑誌, 4(Supplement) (Supplement), 287 - 287, Japanese


• クローン病との鑑別を要した家族性地中海熱の1例

  具 潤亜, 星 奈美子, 大井 充, 竹中 春香, 徳永 英里, 宮崎 はるか, 明本 由衣, 櫻庭 裕丈, 飯田 智哉, 仲瀬 裕志, 児玉 裕三

  日本小腸学会, Nov. 2019, 日本小腸学会学術集会プログラム・抄録集, 57回, 66 - 66, Japanese


• ベーチェット病に伴う仙腸関節炎に対して抗TNFα阻害薬で治療中に、食道穿通病変と回盲部潰瘍が出現し、内科的治療で治療しえた腸管型ベーチェット病の1例

  能瀬 洋子, 井上 綾華, 上田 洋, 宮崎 はる香, 大井 充, 岡野 隆一, 千藤 荘, 明石 健吾, 大西 輝, 星 奈美子, 三枝 淳, 児玉 裕三, 森信 暁雄

  日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 112 - 112, Japanese


• ステロイドへの反応性が良好であった小腸リンパ管拡張症の1例

  中井 沙紀, 具 潤亜, 上田 千勢, 松本 慶, 竹中 春香, 大井 充, 星 奈美子, 児玉 裕三

  日本消化器病学会-近畿支部, Oct. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 111回, 82 - 82, Japanese


• 炎症性腸疾患治療の最前線 当院におけるクローン病に対するウステキヌマブ使用例の検討

  大塚 崇史, 大井 充, 星 奈美子, 児玉 裕三

  日本消化器病学会-近畿支部, Feb. 2019, 日本消化器病学会近畿支部例会プログラム・抄録集, 110回, 68 - 68, Japanese


• 「炎症性腸疾患:シームレスなアプローチを目指して」Special situationにおけるコンセンサスとピットフォール 生物学的製剤投与中の炎症性腸疾患患者における妊娠・出産の経験

  大井 充, 星 奈美子, 児玉 裕三, 青山 伸郎

  (一社)日本消化管学会, Feb. 2019, 日本消化管学会雑誌, 3(Suppl.) (Suppl.), 101 - 101, Japanese


• 胃瘻造設における透明シースを使用した腹壁確認法

  吉崎 哲也, 梅垣 英次, 黒澤 学, 佐藤 悠, 安富 栄一郎, 大塚 崇史, 畑沢 友里, 川浦 由紀子, 小川 浩史, 小原 佳子, 河原 史明, 北村 泰明, 渡邉 大輔, 大井 充, 田中 心和, 石田 司, 森田 圭紀, 豊永 高史, 東 健

  (一社)日本消化器内視鏡学会, Oct. 2016, Gastroenterological Endoscopy, 58(Suppl.2) (Suppl.2), 2003 - 2003, Japanese


• 【IBD治療のcritical point-私ならこうする】 潰瘍性大腸炎 ステロイド抵抗性の見極めと治療方針 次の治療をどう使い分けるか?

  Ooi Makoto, 星奈美子

  (株)日本メディカルセンター, May 2016, 臨床消化器内科, 31(6) (6), 633 - 640, Japanese

  Introduction scientific journal


• 診断に苦慮した好酸球性胃腸炎の1例

  西川倫子, 西川倫子, 大井充, 寺島禎彦, 小畑大輔, 吉江智朗, 吉江智朗, 竹中完, 塩見英之, 藤田剛, 藤田剛, 東健, 森永友紀子

  2016, Gastroenterological Endoscopy (Web), 58(7) (7)


• 抗AIE-75抗体陽性IPEX様症候群を呈したIgA単独欠損症の1女性例

  星 奈美子, 孝橋 道敬, 山入 春香, 具 潤亜, 安冨 栄一郎, 足立 聡一郎, 大塚 崇史, 渡邉 大輔, 大井 充, 吉田 優, 早川 晶, 神保 圭佑, 小林 一郎, 東 健

  日本臨床免疫学会, Sep. 2015, 日本臨床免疫学会会誌, 38(4) (4), 321 - 321, Japanese


• メタボロミクスの現状と炎症/炎症性腸疾患解析への応用

  孝橋 道敬, NISHIUMI SHIN, OOI MAKOTO, Shiomi Yuki, YOSHIE TOMOO, Hoshi Namiko, AZUMA TAKESHI, YOSHIDA MASARU

  Jan. 2014, 炎症と免疫, 22(1) (1), 13 - 16, Japanese

  [Invited]

  Introduction scientific journal


• 【治療に直結する大腸腫瘍診断のストラテジー】 大腸内視鏡検査における病変の拾い上げと見逃し

  池原 伸直, 渡邉 大輔, 吉崎 哲也, 河原 史明, 田中 心和, 大井 充, 吉江 哲郎, 小畑 大輔, Ishida Tsukasa, Morita Yoshinori, Toyonaga Takashi, Azuma Takeshi

  Aug. 2013, 消化器内視鏡, 25(8号) (8号), 1107 - 1113, Japanese

  Introduction scientific journal


• Anti-inflammatory lipid mediators derived from w-6 and w-3 polyunsaturated fatty acids as a treatment option for IBD

  Nishiumi Sin, Kure I, Ishida T, Yoshie T, Ooi M, Kutsumi H, Azuma T, Yoshida Masaru

  Feb. 2011, Antiinflamm Antiallergy Agents Med Chem, 10(1) (1), 66 - 71, English

  [Refereed]

  Introduction scientific journal

• 複数の腸炎モデルマウスに対する漢方薬青黛の効果の検討

  足立 聡一郎, Hoshi Namiko, Inoue Jun, 安冨 栄一郎, 大塚 崇史, Ramesh Dhakhwa, 王 梓, 孔 玲玲, 渡邉 大輔, Ooi Makoto, Yoshida Masaru

  The 8th Annual Meeting of Japanese Society for Inflammatory Bowel disease, Dec. 2017, Japanese, Japanese Society for Inflammatory Boewel Disease, 東京, Domestic conference

  Poster presentation


• 潰瘍性大腸炎(UC)に対するInfliximab(IFX)とTacrolimus(TAC)の長期予後の比較検討

  大塚崇史, Ooi Makoto, Hoshi Namiko

  The 8th Annual Meeting of Japanese Society for Inflammatory Bowel Disease, Dec. 2017, Japanese, Japanese Society for Inflammatory Bowel Disease, 東京, Domestic conference

  Poster presentation


• Increased susceptibility to enteropathogenic bacteria by proton pump inhibitors in the murine model of food poisoning

  安冨 栄一郎, Inoue Jun, 足立 聡一郎, 大塚 崇史, 渡邉 大輔, 具 潤亜, 山入 春香, Ooi Makoto, Hoshi Namiko, 福田 真嗣, Yoshida Masaru, Azuma Takeshi

  25th United European Gastroenterology Week, Oct. 2017, English, United European Gastroenterology, バルセロナ, スペイン, International conference

  Poster presentation


• 腸管ベーチェット病および単純性潰瘍における抗TNFα抗体製剤の有効性と内使用的改善度に関する検討

  大塚崇史, Ooi Makoto, Hoshi Namiko, Yoshida Masaru

  第98回日本消化器内視鏡学会近畿支部例会, Jun. 2017, Japanese, Japan Gastroenterological Endoscopy Society, 神戸, Domestic conference

  Public symposium


• 胃潰瘍穿孔との鑑別が困難であった腸管気腫症の1例

  坂東 正貴, 渡邉 大輔, Tanaka Shinwa, 小原 佳子, 吉崎 哲也, Ooi Makoto, Yoshie Tomoo, Ishida Tsukasa, Ikehara Nobunao, Morita Yoshinori, Toyonaga Takashi, Azuma Takeshi

  第91回日本消化器内視鏡学会近畿地方会, Nov. 2013, Japanese, 日本消化器内視鏡学会近畿支部, 大阪, Domestic conference

  Oral presentation


• APC遺伝子変異が大腸癌の代謝プロファイルに与える影響についての検討

  Yoshie Tomoo, Nishiumi Sin, 孝橋 道敬, Kobayashi Takashi, 池田 篤紀, 坂井 文, Ooi Makoto, Shiomi Yuki, Yoshida Masaru, Azuma Takeshi

  第99回日本消化器病学会総会, Mar. 2013, Japanese, 日本消化器病学会, 鹿児島, Domestic conference

  Oral presentation


• 進行胃癌との鑑別に苦慮した好酸球性胃腸炎の1症例

  西川 倫子, Ooi Makoto, 寺島 禎彦, 小畑 大輔, Yoshie Tomoo, Shiomi Hideyuki, Masuda Atsuhiro, Yoshida Masaru, 藤田 剛, Azuma Takeshi

  日本消化器病学会近畿支部第98回例会, Feb. 2013, Japanese, 日本消化器病学会近畿支部, 神戸, Domestic conference

  Oral presentation


• PPIによる維持療法を行っているGERD患者の臨床的特徴

  河原 史明, 藤田 剛, Ishida Tsukasa, Morita Yoshinori, Yano Yoshihiko, 斉藤 雅也, Okuno Tatsuya, 近藤 靖之, Ooi Makoto, 吉田 志栄, Kutsumi Hiromu, Hayakumo Takanobu, Azuma Takeshi

  第54回日本消化器病学会大会, Oct. 2012, Japanese, 日本消化器病学会, 神戸, Domestic conference

  Poster presentation


• A novel biodegradable esophageal stent in the treatment of a severe refractory esophageal anastomotic stricture in a child: a case report

  大片 祐一, Hisamatsu Chieko, Ooi Makoto, 吉田 志栄, Kutsumi Hiromu, 西島 栄治

  23rd Congress of the Asian Association of Pediatric Surgeons, Oct. 2012, English, Asian Association of Pediatric Surgeons, Seoul, International conference

  Poster presentation


• 同時多発癌を合併したCrohn病の一例

  山本 恭孝, Okuno Tatsuya, Yoshie Tomoo, 平野 仁崇, 池田 篤紀, 孝橋 道敬, 神澤 真紀, Ooi Makoto, Ikehara Nobunao, Yamashita Kimihiro, 大林 千穂, Yoshida Masaru, 黒田 大介, 藤田 剛, Kakeji Yoshihiro, Yokozaki Hiroshi, Azuma Takeshi

  日本消化器病学会近畿支部第97回例会, Sep. 2012, Japanese, 日本消化器病学会近畿支部, 京都, Domestic conference

  Oral presentation


• クローン病発症から23年を経て同時性多発大腸癌を併発した1例

  Yamashita Kimihiro, Ooi Makoto, Yoshie Tomoo, Kim Kiyonori, Sumi Yasuo, Suzuki Satoshi, 黒田 大介, Yoshida Tsuyoshi, Azuma Takeshi, Kakeji Yoshihiro

  兵庫IBDカンファレンス, May 2012, Japanese, 神戸, Domestic conference

  Public discourse


• 食道閉鎖術後の難治性吻合部狭窄に対して生分解性食道用ステント（BDステント）を使用した1例

  大片 祐一, Hisamatsu Chieko, Ooi Makoto, 吉田 志栄, Kutsumi Hiromu, 西島 栄治

  第31回日本小児内視鏡学会・手術手技研究会, Oct. 2011, Japanese, 日本小児内視鏡外科・手術手技研究会, 大阪, Domestic conference

  Oral presentation


• 当院における食道表在癌の内視鏡的治療について

  Morita Yoshinori, Ooi Makoto, Tanaka Shinwa, Shiomi Yuki, Ishida Tsukasa, Kutsumi Hiromu, Inokuchi Hideto, Toyonaga Takashi, Azuma Takeshi

  第76回 日本消化器内視鏡学会総会, Oct. 2008, Japanese, 日本消化器内視鏡学会, 東京, Domestic conference

  Poster presentation


• 自己免疫性膵炎はミクリッツ病を高率に合併する？

  Kutsumi Hiromu, Azuma Takeshi, Okuno Tatsuya, Masuda Atsuhiro, Ooi Makoto, Yano Yoshihiko, Yoshida Masaru, Seo Yasushi, Tamura Takao, Inokuchi Hideto

  第94回 日本消化器病学会総会, May 2008, Japanese, 日本消化器病学会, 福岡, Domestic conference

  Oral presentation

• プロスタグランジン合成酵素に着目したクローン病の新規治療法の開発

  大井 充

  日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2023 - 31 Mar. 2026


• Development of colorectal cancer prevention methods by modifying the intestinal environment

  Ooi Makoto

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2019 - 31 Mar. 2022

  It is believed that diet and intestinal bacteria influence the development of colorectal cancer. We hypothesized that if the mechanism could be elucidated, it would be possible to prevent colorectal cancer by changing the intestinal environment through diet and other means. In this study, using ApcMin/+ mice as a tumor model, we investigated its involvement in tumorigenesis by using amino acid-restricted diet, amino acid transporter-deficient mice, and mice deficient in GPR43, a short-chain fatty acid receptor. The results showed that GPR43-deficient mice have increased tumors, while LAT1-deficient mice have decreased tumors. We also confirmed that restricting specific branched-chain amino acids also reduced tumors.